CN108187151A - A kind of stent of medication coat - Google Patents
A kind of stent of medication coat Download PDFInfo
- Publication number
- CN108187151A CN108187151A CN201810064908.7A CN201810064908A CN108187151A CN 108187151 A CN108187151 A CN 108187151A CN 201810064908 A CN201810064908 A CN 201810064908A CN 108187151 A CN108187151 A CN 108187151A
- Authority
- CN
- China
- Prior art keywords
- stent
- gefitinib
- coating
- drug
- intravascular stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
A kind of intravascular stent of drug containing coating, intravascular stent matrix are bare metal or alloy, and Gefitinib medication coat is coated in intravascular stent.Gefitinib drug forms coating together with polylactic acid carrier, and Gefitinib drug and the mass ratio of polylactic acid carrier are 5mg/g.Gefitinib and its carrier polylactic acid are dissolved in the ethanol solution of 100WT% and are heated to 40-80 DEG C, it is more than hour to be kept for 1；Metallic support matrix is fixed and held at 60 ± 10 DEG C, medication coat liquid is dropped on rest body and is dried, dropping to coating layer thickness 3 10 times repeatedly reaches 10 100 microns；Or metallic support is immersed in medication coat liquid, rear drying forms coating, more than 3 10 times to the coating layer thickness needed repeatedly.
Description
Technical field
The present invention relates to medical equipment, it is a kind of by function medicament coating load in the alloys grid such as common CoPt, stainless steel
A kind of drug loading stent formed on the common stent base material of composition.
Background technology
United States Patent (USP) 5697967 just discloses a kind of such drug loading stent.United States Patent (USP) 9204982 discloses pair
The method that this kind of stent carries out infusion of medicine.Lei Pasu is supported on bare bracket using in the blood vessel, can effectively be inhibited again
Narrow generation.The periphery stent of Clinical practice is mostly bare metal stent, but Stent is limited in stent for a long time at present
Restenosis (in-stent restenosis, ISR), 20% after bare metal stent (bare metal stent, BMS) implantation
In-stent restenosis (in-stent restenosis, ISR) can occur for~30% patient, become the weight that interventional treatment faces
Want problem [1].Research shows that coating stent of medicine (drug-eluting stents, DES) can further reduce the generation of ISR
Rate [2], but DES is still faced with late period thrombus in stents (late stents thrombosis, LST), blood in the late period stent of pole
The problems such as bolt (very late stent thrombosis, VLST) [3], influence interventional treatment curative effect.Foreign countries, which also have, to be studied
The coating stent of medicine of the drugs such as taxol.Taxol DES and sirolimus (Siromlius) and its derivative DES are current
Clinically more common intravascular stent, action principle is inhibits vascular smooth muscle cell proliferation and migration.With the naked branch of conventional metals
Frame is compared, they can inhibit endometrial hyperplasia, reduces the generation of ISR.However, patient to being implanted into these coating stent of medicine with
Visit find, late endothelial cell cannot be completely covered as the coating stent of medicine it is maximum the shortcomings that.Endothelialization (re-
Endothelialization, RE) it is not all due to the nonspecific antiproliferative effect of eluted substance, these drugs are inhibiting
While vascular smooth muscle cell proliferation, inhibit the growth of vascular endothelial cell.
Bibliography
[1]F.Alfonso,M.J.Perez-Vizcayno,A.Cruz,J.Garcia,P.Jimenez-Quevedo,
J.Escaned,R.Hernandez,Treatment of patients with in-stent restenosis,
EuroIntervention 5(Suppl.D)(2009)D70–D78.
[2]S.McGinty,S.McKee,R.M.Wadsworth,C.McCormick,Modelling drug-eluting
Stents,Math.Med.Biol.28(1)(2011)1–29.
[3]Takano M,Yamamoto M,Inami S,et al.Long-Term Follow-Up Evaluation
After Sirolimus-Eluting Stent Implantation by Optical Coherence Tomography
[J].Jacc,2008(9):968-969.
Invention content
The present invention seeks to propose a kind of coating stent of medicine, coating stent of medicine of the invention includes stent and coating
Medication coat on stent, described medication coat are the polymer containing Gefitinib, are having substantially no effect on endothelial cell
While growth, effectively inhibit the proliferation of vascular smooth muscle cells, so as to have the function that inhibit in-stent restenosis.
The technical scheme is that：A kind of stent of drug containing coating, i.e., using NEW TYPE OF COMPOSITE medication coat functionalization
Intravascular stent, intravascular stent matrix is common bare metal or alloy (or its other timbering material), in intravascular stent metal mesh
Place is coated with Gefitinib medication coat.
Gefitinib drug forms coating, the mass ratio of Gefitinib drug and polylactic acid carrier together with polylactic acid carrier
Example is 5mg/g.
The preparation method of the intravascular stent of the drug containing coating, typical combination drug coating liquid manufacturing process
It is that Gefitinib and its carrier polylactic acid are dissolved in the ethanol solution of 100WT% to and be heated to 40-80 DEG C of holdings is 1 small
When more than；Metallic support matrix is fixed and held at 60 ± 10 DEG C, medication coat liquid is dropped on rest body and is dried, instead
It drops to coating layer thickness and reaches 10-100 microns for multiple 3-10 times；Or metallic support is immersed in medication coat liquid, it is rear to dry
Coating is formed, repeatedly the more coating layer thicknesses to needs of 3-10.
Metallic support is immersed in combination drug coating liquid, rear drying forms coating, and more times of 3-10 is to needing repeatedly
Coating layer thickness.Manufacturing cost invention Gefitinib coating bracket GES.
Gefitinib (Gefitinib) is that a kind of oral epidermal growth factor recipient tyrosine kinase (EGFR-TK) inhibits
Agent is clinically used for the chemotherapy of Locally Advanced or Metastatic Nsclc at present, has experiment in vitro to show Gefitinib and purple
China fir alcohol compares the proliferation that can inhibit vascular smooth muscle cells (SMC) more specificly, and to the cell of vascular endothelial cell (VEC)
Toxic effect is less than taxol.This research observes gefitinib coating stent of medicine in miniature pig femoral artery model support
The preventive effect of restenosis, there is not been reported both at home and abroad for the research in relation to this respect.
The present invention is a kind of intravascular stent using newtype drug coating functionalization, and in vitro test and animal experiment show
The present invention while endothelial cell growth is had substantially no effect on, can effectively inhibit the proliferation of vascular smooth muscle cells, so as to reach
Inhibit the effect of in-stent restenosis.
The appearance of DES is known as another " milestone " in blood vessel intervention field, and DES is that surface is combined with carrying drug
The stent of carrier becomes a drug pond after diseased region is placed in, and constantly locally discharges drug to lesion, has targeting
Well, the advantages that effective treatment time is long, and systemic side effects are small.The mechanism of in-stent restenosis is not yet elucidated with completely, there is research
The hyperplasia and ISR for showing inner membrance have substantial connection.The hyperplasia of inner membrance is affected there are many factor, and smooth muscle cell
Proliferation and migrating play extremely important effect [5].Taxol DES and sirolimus (Siromlius) and its derivative
DES is current clinically more common intravascular stent, and action principle is inhibits vascular smooth muscle cell proliferation and migration.With tradition
Bare metal stent is compared, they can inhibit endometrial hyperplasia, reduces the generation of ISR.However, to being implanted into these coating stent of medicine
The follow-up of patient finds, late endothelial cell cannot be completely covered as the coating stent of medicine it is maximum the shortcomings that.Endothelialization
(re-endothelialization, RE) is not all due to the nonspecific antiproliferative effect of eluted substance, these drugs exist
While inhibiting vascular smooth muscle cell proliferation, inhibit the growth of vascular endothelial cell.DES is made using Gefitinib in this experiment, and
Confirm that GES can effectively inhibit the generation of in-stent restenosis from color-Doppler ultrasound, CTA, histopathology angle, without in influence
Pi Hua.
This research passes through experiment in vitro, it is determined that best drug concentration, to reach inhibition vascular smooth muscle cell proliferation
While, have substantially no effect on the normal growth of vascular endothelial cell.After GES is implanted into miniature pig femoral artery, postoperative color ultrasound in January
Blood flow is unobstructed in prompting GES, and flow velocity is normal.Postoperative CTA in March promptings stent is in place, is deformed without apparent displacement, stent diameter is just
Often, interior blood flow is unobstructed.Belt supporting frame vascular specimen is taken out simultaneously, and histopathological analysis prompting GES groups (n=10) are compared to BMS
Group (n=10), in blood vessel diameter, Injury score no significant difference (P>0.05), but GES groups Lumen Area significantly increases compared with BES groups
Add, inner film thickness, neointimal area are reduced compared with BES groups on stent.It can be seen that in 3 months after stenter to implant, GES can have
Effect inhibits endometrial hyperplasia, avoids the generation of in-stent restenosis.Medicament selection for DES provides a kind of new thinking.
Description of the drawings
Fig. 1 is GES scanning electron microscope amplifying observation figure of the present invention.
Specific embodiment
1.1 experiment material
1.1.1 cell strain and main agents：Pig stem cell, fetal calf serum, DMEM culture solutions, EBM-2 culture solutions,
PDGF-BB growth factors, PBS, pancreatin, FITC, DAPI nuclear fuel, MTT, DMSO.
1.1.2 drug, carrier and stent：Gefitinib, polylactic acid, 100% ethyl alcohol, 3cm*2.5mm coronary arterys ball expand stent
(Buma)
1.1.3 experimental animal：This experiment uses Ba-Ma mini pig, and male and female are unlimited, weight 20-25kg, purchased from Nanjing drum tower
Hospital's animal experimental center
1.2 experimental method
1.2.1 vascular smooth muscle cells, the induction of vascular endothelial cell and identified by immunofluorescence：By the pig bone of normal growth
Marrow stem cell, respectively with the DMEM culture solutions of the growth factor containing PDGF-BB, EBM-2 culture solution cultures, the parameter of cell incubator
It is adjusted to 5%CO2, environment temperature is adjusted to 37 DEG C.It is induced to differentiate into vascular smooth muscle cells and vascular endothelial cell.And
Row immunofluorescence analysis.Wherein vascular smooth muscle cells specificity primary antibody is α-actin, and vascular endothelial cell specificity primary antibody is
VWF and CD34.
1.2.2 the preparation of coating stent of medicine and scanning electron microscopic observation：This experiment prepares stent using dip coating.By coronary artery
Bare bracket disinfection is spare.By Gefitinib and its carrier polylactic acid with the mass ratio of 0,1mg/g, 2mg/g, 5mg/g, 10mg/g
It is dissolved in 100% ethyl alcohol of 100ml, stent is immersed respectively in the ethyl alcohol of the drug containing concentration gradient, 37 DEG C of dip-coatings are for 24 hours.It takes out
Each drug concentration gradient stent fully air-dries, the combination situation of row scanning electron microscopic observation drug and stent.And by all stents again
Secondary disinfection is spare.
1.2.3MTT method determines suitable Gefitinib drug concentration：By the dense of 0,1mg/g, 2mg/g, 5mg/g, 10mg/g
The stent of gradient is spent, is respectively implanted in 50ml PBS, 37 DEG C of constant temperature stir 72h, and leaching liquor is made.And with each concentration gradient GES
Leaching liquor is culture substrate, cultivates SMC and VEC respectively, and continuous row MTT on the four is tested, growth period cell of taking the logarithm is made 1
×104Cell suspension is inoculated in 96 orifice plates, per 100 μ l of hole to cell it is adherent after, old culture solution is abandoned in suction, adds in various concentration ladder
Extract culture medium (, 1mg/g, 2mg/g, 5mg/g, 10mg/g) is spent, after continuing culture 24,48,72,96h, adds MTT liquid per hole
20 μ l continue to be incubated 4h, and every hole culture solution is abandoned in suction, is added in the DMSO of 150 μ l, until shaking 20min on shaking table, is measured each group
Absorbance under OD490.Inhibiting rate of each concentration gradient leaching liquor to MSC and EPC is calculated, is chosen according to MTT results most suitable
Gefitinib drug concentration.
1.2.4GES it is implanted into pig femoral artery：GES is prepared by above-mentioned optimum concentration and is sterilized.It is small-sized to choose 10 bars of horses
After pig, intramuscular injection ketamine (100mg) and droperidol cacaine (5mg) anesthesia, pig dorsal position is fixed on surgical plate.
After preserved skin and disinfection bilateral inguinal, groin vertical incision, blunt separation muscle gap, exposure bilateral carotid arteries, around band are taken
Spare, after whole body test tube of hepari (100U/kg), pekinese folder blocks the nearly heart section of arteria carotis and distal end, before the femoral artery of blocking
Wall takes row notch, and length is about 5mm, to proximal part be placed in 0.014mm seal wires, it would be desirable to the GES of release by seal wire send to
The blood vessel of pre-release goes out, and sacculus is opened under the pressure of 10 atmospheric pressure, and stent is discharged to Endovascular, withdraws from release sacculus.
Art, which finishes, takes 8-0prolene lines continuously to suture arteria carotis row notch, and whether open blood flow observation blood vessel is unobstructed, and it is narrow to whether there is part
It is narrow, carefully after hemostasis, successively close femoral artery notch.Vein gives penicillin 800,000 U before operation is completed, postoperative to give Ah Si
Woods antiplatelet (300mg/d).
1.2.5 postoperative check in January color ultrasound：Postoperative January, intramuscular injection ketamine (100mg) and droperidol cacaine
After (5mg) anesthesia and preserved skin.All animal row bilateral femoral arterial color ultrasound examinations.
1.2.6 postoperative row in March CTA is checked：After basal anaesthesia, Iodophor alcohol is injected in miniature pig auricular vein postoperative March
50ml, the parallel three-dimensional reconstruction of the double Thoracic Limb Arteries of CT scan.
1.2.7 histological examination：Postoperative March, exposure implantation stent femoral artery section, visually observe artery it is unobstructed whether
And its visual condition.The sample of femoral artery containing brace sections is cut, is equally divided into 3 sections.First segment is fixed on 10% formalin solution
In, in rear embedding to methyl methacrylate, hard tissue slicing machine-cut piece is to after 50 μm, the dyeing of row Hematoxylin-eosin.Second segment
Stent sample longitudinal incision, tiled scaffold are dipped in 1.6% glutaraldehyde, prepare the life of row scanning electron microscopic observation endothelial cell
Long situation.Third section stent sample row immunohistochemical analysis
2nd, result
2.1 identified by immunofluorescence results
Pig vascular smooth muscle cells and endothelial cell growth are in good condition, and immunofluorescence results prompting smooth muscle cell α-
Actin is positive, and endothelial cell CD34, vWF are positive, and result above confirms that two kinds of cells meet phenotype.
The preparation of 2.2GES and scanning electron microscope result
Coating stent of medicine, scanned Electronic Speculum inspection, it is seen that drug granule is uniformly distributed successfully are made according to the above method
In BMS surfaces, and BMS surfaces are still relatively smooth, do not influenced (Fig. 1) by preparation process.
2.3MTT result
This experiment probes into different pharmaceutical concentration GES to VSMC and VEC lethal effects using mtt assay, to determine suitable medicine
Object concentration.The inhibiting rate to two kinds of cells of each concentration gradient GES, it is seen that Gefitinib can significantly inhibit the growth of VSMC, and
It is weaker to the growth inhibition effect of VEC.Gefitinib is positively correlated VSMC inhibiting effect and drug concentration, action time, so
And as drug concentration excessively high (10mg/g), obvious inhibiting effect is also there has been to VEC, 96h inhibiting rates are 15%.It is comprehensive
It closes and considers that drug influences VSMC and VEC, select drug concentrations of the 5mg/g as follow-up zoopery.
2.4 postoperative B ultrasound situations
Postoperative January checks B ultrasound, it is seen that blood flow is unobstructed in GES stents, and flow velocity is normal.
Claims (3)
1. a kind of intravascular stent of drug containing coating, it is characterized in that intravascular stent matrix is bare metal or alloy, in intravascular stent
Coated with Gefitinib medication coat.
2. the intravascular stent of drug containing coating according to claim 1, it is characterized in that Gefitinib drug is carried with polylactic acid
Body forms coating together, and Gefitinib drug and the mass ratio of polylactic acid carrier are 5mg/g.
3. the preparation method of the intravascular stent of drug containing coating according to claim 1, it is characterized in that it is typical compound
Medication coat liquid manufacturing process is that Gefitinib and its carrier polylactic acid are dissolved in the ethanol solution of 100WT% and are heated
It is more than hour to be kept for 1 to 40-80 DEG C；Metallic support matrix is fixed and held at 60 ± 10 DEG C, medication coat liquid is dripped
It is dried on rest body, dropping to coating layer thickness 3-10 times repeatedly reaches 10-100 microns；Or metallic support is immersed in medicine
In object coating liquid, rear drying forms coating, repeatedly the more coating layer thicknesses to needs of 3-10.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810064908.7A CN108187151A (en) | 2018-01-23 | 2018-01-23 | A kind of stent of medication coat |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810064908.7A CN108187151A (en) | 2018-01-23 | 2018-01-23 | A kind of stent of medication coat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108187151A true CN108187151A (en) | 2018-06-22 |
Family
ID=62590464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810064908.7A Pending CN108187151A (en) | 2018-01-23 | 2018-01-23 | A kind of stent of medication coat |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108187151A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112094B1 (en) * | 1998-09-10 | 2003-06-25 | Schering Aktiengesellschaft | Coated medical devices and implants |
| CN1429547A (en) * | 2002-01-04 | 2003-07-16 | 中国科学院化学研究所 | Coronary artery skeleton medicinal coating for preventing restenosis of blood vessel |
| CN101279112A (en) * | 2008-05-15 | 2008-10-08 | 哈尔滨工程大学 | Intravascular stent with PLGA blend medicament eluting surface coating |
| CN101485902A (en) * | 2009-02-11 | 2009-07-22 | 乐普（北京）医疗器械股份有限公司 | Biological degradable metal stent coated with rapamycin-probucol composite medicament |
| CN103961355A (en) * | 2014-05-04 | 2014-08-06 | 杨军 | Application of gefitinib in medicine for suppressing excessive multiplication of smooth muscle cells at injured part of blood vessel and/or promoting endothelialization of injured blood vessel |
| CN203842076U (en) * | 2014-05-04 | 2014-09-24 | 杨军 | Intravascular coating stent containing gefitinib layer |
-
2018
- 2018-01-23 CN CN201810064908.7A patent/CN108187151A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112094B1 (en) * | 1998-09-10 | 2003-06-25 | Schering Aktiengesellschaft | Coated medical devices and implants |
| CN1429547A (en) * | 2002-01-04 | 2003-07-16 | 中国科学院化学研究所 | Coronary artery skeleton medicinal coating for preventing restenosis of blood vessel |
| CN101279112A (en) * | 2008-05-15 | 2008-10-08 | 哈尔滨工程大学 | Intravascular stent with PLGA blend medicament eluting surface coating |
| CN101485902A (en) * | 2009-02-11 | 2009-07-22 | 乐普（北京）医疗器械股份有限公司 | Biological degradable metal stent coated with rapamycin-probucol composite medicament |
| CN103961355A (en) * | 2014-05-04 | 2014-08-06 | 杨军 | Application of gefitinib in medicine for suppressing excessive multiplication of smooth muscle cells at injured part of blood vessel and/or promoting endothelialization of injured blood vessel |
| CN203842076U (en) * | 2014-05-04 | 2014-09-24 | 杨军 | Intravascular coating stent containing gefitinib layer |
Non-Patent Citations (1)
| Title |
|---|
| 王苏燕: "吉非替尼对血管平滑肌细胞及内皮细胞增殖的影响及其机制的初步探讨", 《中国优秀硕士学位论文全文数据库 医药卫生辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mani et al. | Coronary stents: a materials perspective | |
| Kornowski et al. | In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia | |
| US20050180919A1 (en) | Stent with radiopaque and encapsulant coatings | |
| JP5329435B2 (en) | Coronary stent with asymmetric drug release controlled coating | |
| Moretti et al. | Cre8™ coronary stent: preclinical in vivo assessment of a new generation polymer-free DES with Amphilimus™ formulation | |
| US7662178B2 (en) | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis | |
| Cardinal et al. | Tissue-engineered vascular grafts as in vitro blood vessel mimics for the evaluation of endothelialization of intravascular devices | |
| WO2006052521A2 (en) | Medical devices and compositions for treating restenosis | |
| EP2380528A1 (en) | Medicament eluting apparatus with micro-hole structure capable of storing and releasing multiple medicines and preparation method | |
| CN102151185A (en) | Biodegradable stent with laminated coatings | |
| Jeong et al. | Augmented re-endothelialization and anti-inflammation of coronary drug-eluting stent by abluminal coating with magnesium hydroxide | |
| Hermawan et al. | Degradable metallic biomaterials: the concept, current developments and future directions | |
| Jantzen et al. | Use of autologous blood-derived endothelial progenitor cells at point-of-care to protect against implant thrombosis in a large animal model | |
| US20080085293A1 (en) | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor | |
| Chen et al. | Assessment of structure integrity, corrosion behavior and microstructure change of AZ31B stent in porcine coronary arteries | |
| US20040213826A1 (en) | Medical devices and methods for inhibiting proliferation of smooth muscle cells | |
| US20110321181A1 (en) | Device to be placed in blood vessel, angiostenosis model using same and method for making model | |
| CN100493627C (en) | Coronary artery medicinal-coating stent | |
| US20050154451A1 (en) | Medical devices to treat or inhibit restenosis | |
| US20050214343A1 (en) | Medical devices comprising a protein-tyrosine kinase inhibitor to inhibit restonosis | |
| CN108187151A (en) | A kind of stent of medication coat | |
| US20050228490A1 (en) | Medical devices to treat or inhibit restenosis | |
| Henn et al. | Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents | |
| JP2005538756A (en) | Medical device comprising a protein-tyrosine kinase inhibitor for inhibiting restenosis | |
| US20050149174A1 (en) | Medical devices to treat or inhibit restenosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180622 |